Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Extension Study of Etrasimod in Japanese Ulcerative Colitis
jRCT2071200080Phase 3Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrasimod 2 mg QD with Placebo (2 arms). Primary endpoint: Clinical remission rate. Started Dec 2020; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071200080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200080.